Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis
NCT ID: NCT05730010
Last Updated: 2023-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
289 participants
OBSERVATIONAL
2023-04-16
2023-06-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ctDNA Monitoring in Early Breast Cancer
NCT04353557
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer
NCT05079074
Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy
NCT05649475
Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
NCT06087120
Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia
NCT05050890
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Self- reported history of receiving chemotherapy for breast cancer
* Self- reported history of chemotherapy completed at least 6 months ago but no more than 10 years ago
* Able to complete an online survey
* English speaking
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tarah J Ballinger, MD
Assistant Professor of Clinical Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTO-IUSCCC-0803
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.